RecruitingPhase 2NCT05304234

Liver Cancer Disparities in American Indian and Alaska Native Persons

Sponsor

University of Washington

Enrollment

200 participants

Start Date

Apr 1, 2022

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma Hepatitis B Cirrhosis, Liver

Summary

We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study looks at liver cancer (hepatocellular carcinoma, HCC) screening disparities in American Indian and Alaska Native people, who have high rates of liver disease but are underrepresented in cancer research. It evaluates better screening approaches for this high-risk community. **You may be eligible if...** - You are between 18 and 75 years old - You have cirrhosis (liver scarring from any cause) or chronic hepatitis B infection - You are considered at high risk for liver cancer - You are able to give informed consent **You may NOT be eligible if...** - You have already been diagnosed with liver cancer - You have had an organ transplant - Your liver disease is very severe (high MELD or CTP scores) - You have poor kidney function or a contraindication to MRI - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.